Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Needham Maintains Buy on NextCure, Lowers Price Target to $6

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $12 to $6.

byBenzinga Newsdesk

November 4, 2022

1 minute read

Needham analyst Gil Blum maintains NextCure (NASDAQ:NXTC) with a Buy and lowers the price target from $12 to $6.

Why Catalyst Pharmaceuticals Shares Are Moving

By Henry Khederian

Today, 4:41 PM

Catalyst Pharmaceuticals Inc (NASDAQ: CPRX) shares are trading higher by 9.66% to $15.72 Thursday morning after the company reported better-than-expected fourth-quarter results.

CPRX

Rush Enterprises Q4 EPS $1.74 Beats $1.49 Estimate, Sales $1.90B Beat $1.82B Estimate

By Bill Haddad

Today, 4:41 PM

Rush Enterprises (NASDAQ:RUSHA) reported quarterly earnings of $1.74 per share which beat the analyst consensus estimate of $1.49 by 16.78 percent. This is a 47.46 percent increase over earnings of $1.18 per share from

RUSHA